Our long-term commitment to instigating, supporting and delivering cutting-edge research means there are a wide variety of research projects under way at Great Ormond Street Hospital (GOSH) at any given time.
Every year around two hundred research projects are started, while at any one time there are roughly five hundred research projects active at the Trust.
All research taking place at GOSH is structured around our six clinical areas:
- Critical Care and Cardio-Respiratory
- Diagnostic and Therapeutic Services
- Infection, Cancer and Immunity
- Developmental Biology and Cancer
- Developmental Neurosciences
- Genetics and Genomic Medicine
- Infection, Immunity, Inflammation and Physiological Medicine
- Population, Policy and Practice
Clinical trial performance
The National Institute for Health Research (NIHR)'s aim is to ensure clinical research is conducted efficiently and effectively, thereby enhancing the attractiveness of the UK as a centre for research. All NHS organisations in receipt of NIHR funding are required to report their performance against two metrics on a quarterly basis:
Performance in Initiating: the length of time it has taken to open studies where GOSH has been selected as a site in the past 12 months.
Performance in Delivering: the number of commercial contract clinical trials that recruit their agreed number of participants within the agreed time frame.
Further information on why this is measured, and the NIHR’s official guidance and requirements, can be found on the NIHR website
We submit quarterly reports to the NIHR setting out our performance against these metrics.
Please note: In light of the unprecedented efforts made across the system to tackle COVID-19, in March the NIHR postponed the submission and publication deadline for the Performance in Initiating and Delivering (PID) Q4 19-20 and Q1 20-21 reporting exercises. In July the Department of Health and Social Care confirmed that the platform for Q4 19-20, Q1 20-21 and Q2 20-21 had reopened with a deadline for all three submissions of 30 October 2020 (the original Q2 deadline). The information for all three submissions must also be displayed on our website, therefore six reports shall be displayed one after the other this quarter.
These data are available below and will be updated quarterly.
1920 Q4 Performance in Initiation (.xlsx) (19.9 KB)
2021 Q1 Performance in Initiation (.xlsx) (23.4 KB)
2021 Q2 Performance in Initiation.xlsx (.xlsx) (21.8 KB)
For clinical trials where GOSH was selected as a site between 01 April 2019 and 31 March 2020 (Q4), 01 July 2020 - 30 June 2020 (Q1), and 01 October 2019 - 30 September 2020 (Q2). Once we have been selected, we aim to confirm the trial within 40 days and recruit a patient within 30 days of confirming as a site. If the benchmarks were not met, for any reason(s), then we have provided information as to how this occurred and are working with sponsors and clinical teams to refine and improve our processes where appropriate.
1920 Q4 Performance in Delivery (.xlsx) (18.3 KB)
2021 Q1 Performance in Delivery (.xlsx) (17.7 KB)
2021 Q2 Performance in Delivery (.xlsx) (20.5 KB)
For commercial contract clinical trials that closed to recruitment between 01 April 2019 and 31 March 2020 (Q4), 01 July 2019 – 30 June 2020 (Q1) and 01 October 2019 – 30 September 2020 (Q2). Commercial contract clinical trials will usually have a contractually agreed target number of participants, and a date agreed to recruit them. Once the trial closes to recruitment, we report whether we've met these targets and the reason(s) why we have not been able to meet them if appropriate.